COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

PET Imaging to Determine the Role of PET in the Assessment of Regional Disease in Breast Cancer (PET PREDICT Trial)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00201942
Recruitment Status : Completed
First Posted : September 20, 2005
Last Update Posted : October 18, 2007
Ontario Ministry of Health and Long Term Care
Information provided by:
Ontario Clinical Oncology Group (OCOG)

Brief Summary:

The overall goal of this study is to determine how FDG-PET can be incorporated into the assessment of the axilla in the staging and treatment of women with early stage breast cancer.

A multicentre, prospective, diagnostic accuracy study will be conducted evaluating the ability of positronic emission tomography using fluorodeoxyglucose (FDG-PET) to detect the presence or absence of axillary lymph node metastases in newly diagnosed breast cancer patients with no clinical evidence of spread of disease beyond the breast.

Condition or disease Intervention/treatment Phase
Breast Cancer Procedure: PET scan Phase 3

Detailed Description:
Patients will have histologic confirmation of invasive breast cancer and will have a FDG-PET scan prior to axillary node assessment. All patients will have a sentinel node biopsy if any sentinel nodes can be located. Patients with a positive sentinel node will have an axillary node dissection. The results of the PET will be compared to the reference standard of histologic examination of all excised (sentinel and non-sentinel) axillary lymph nodes which will be referred to as axillary node assessment. Sensitivity, specificity, positive and negative predictive values for PET-FDG will be determined.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 336 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Diagnostic
Official Title: A Prospective Study to Determine the Role of 2-[18F]Fluoro-2-Deoxy-D-Glucose (FDG)Positron Emission Tomography (PET)in the Assessment of Regional Nodal Spread of Disease in Breast Cancer Patients
Study Start Date : February 2005
Actual Study Completion Date : May 2007

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Breast Cancer

Primary Outcome Measures :
  1. The primary outcomes are the sensitivity and specificity of FDG-PET in axillary node assessments using axillary node assessment [Sentinel Node Biopsy(SNB) with or without Axillary Node Dissection (AND)] as the reference standard.

Secondary Outcome Measures :
  1. Patients with positive FDG-PET in non-axillary nodal areas;
  2. Patients with positive FDG-PET in other non-nodal areas;
  3. Patients with positive FDG-PET in the residual breast tissue.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Histologic diagnosis of invasive breast cancer,
  • Resectable primary cancer.

Exclusion Criteria:

  • The diagnosis of invasive breast cancer was made more than 3 months prior to registration,
  • Patient and/or surgeon are not willing to proceed with a SNB or AND after the PET scan is completed,
  • Patient and/or surgeon are not willing to proceed with a level I and II AND if the SNB is positive, if the PET scan shows increased uptake in the ipsilateral axilla, or if the surgeon is still gaining experience in the performance of SNB,
  • SNB or AND has already been done,
  • Chemotherapy has been given or will be given prior to PET scan or SNB or AND,
  • Significant serious concurrent medical problems (e.g., uncontrolled diabetes),
  • Patient is pregnant or lactating,
  • Patient is unable to lie supine and with both arms above their heads for PET scan,
  • Known hypersensitivity to FDG,
  • Clinical evidence of regional nodal metastases (fixed, matted axillary nodes),
  • Clinical evidence of distant metastases.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00201942

Layout table for location information
Canada, Ontario
St. Joseph's
Hamilton, Ontario, Canada, L8N 4A6
Juravinski Cancer Centre
Hamilton, Ontario, Canada, L8V 1C3
Kingston Regional Cancer Centre
Kingston, Ontario, Canada, K7L 5P9
London Regional Cancer Centre
London, Ontario, Canada, N6A 4L6
Ottawa Regional Cancer Centre
Ottawa, Ontario, Canada, K1Y 4K7
North York
Toronto, Ontario, Canada, M2J 1V1
Sunnybrook Regional Cancer Centre and Women's College
Toronto, Ontario, Canada, M4N 3M5
St. Michael's
Toronto, Ontario, Canada, M5B 1W8
Mount Sinai Hospital
Toronto, Ontario, Canada, M5G 1X5
Princess Margaret Hospital
Toronto, Ontario, Canada, M5G 2M9
Sponsors and Collaborators
Ontario Clinical Oncology Group (OCOG)
Ontario Ministry of Health and Long Term Care
Layout table for investigator information
Study Chair: Kathleen Pritchard, MD Sunnybrook Regional Cancer Centre
Principal Investigator: Claire Holloway, MD Sunnybrook Regional Cancer Centre
Principal Investigator: David McCready, MD Princess Margaret Hospital, Canada
Principal Investigator: Jim Julian, M.Math. McMaster University
Principal Investigator: Mark N Levine, MD Ontario Clinical Oncology Group (OCOG)
Principal Investigator: Wendy Shelley, MD Kingston Regional Cancer Centre
Principal Investigator: Karen Gulenchyn, MD, PhD McMaster University
Principal Investigator: Frances O'Malley, MD MOUNT SINAI HOSPITAL
Layout table for additonal information Identifier: NCT00201942    
Other Study ID Numbers: CTA-Control-092493
First Posted: September 20, 2005    Key Record Dates
Last Update Posted: October 18, 2007
Last Verified: October 2007
Keywords provided by Ontario Clinical Oncology Group (OCOG):
Breast Cancer
Positronic Emission Tomography
Additional relevant MeSH terms:
Layout table for MeSH terms
Breast Neoplasms
Neoplasms by Site
Breast Diseases
Skin Diseases